Evidence map›Paper›PMID 40911258›Full record

ArticleOncology and therapy2025

Pembrolizumab-Induced High Inflammatory Panmyelitis: Contribution of Neurochemical Markers Predicting Severity of Central Nervous Affection.

Beate Hagenkötter, Jérôme De Sèze, Faten Hammami, Timothée Klopfenstein, Souheil Zayet

Abstract read
In one paragraph

Article in Oncology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Beate HagenkötterDepartment of Neurology, Nord Franche-Comté Hospital, Belfort, France. beate.hagenkotter@hnfc.fr.ORCID http://orcid.org/0000-0002-8839-3229
Jérôme De SèzeDepartment of Neurology and Clinical Investigation Center, INSERM 1434, Strasbourg University Hospitals Hautepierre, Strasbourg, France.
Faten HammamiDepartment of Radiology, Nord Franche-Comté Hospital, Belfort, France.
Timothée KlopfensteinDepartment of Infectious Diseases, Nord Franche-Comté Hospital, Belfort, France.
Souheil ZayetDepartment of Infectious Diseases, Nord Franche-Comté Hospital, Belfort, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This is the first documented case of recurrent, severe, and highly inflammatory panmyelitis induced by pembrolizumab. A 41-year-old woman with nodular melanoma developed tetraparesis after three cycles of pembrolizumab treatment. Spinal magnetic resonance imaging (MRI) revealed extensive longitudinal panmyelitis, and cerebrospinal fluid analysis showed markedly elevated cell counts (3900/mm

Indexed as

MelanomaNeurochemical markersPanmyelitisPembrolizumab

Identifiers

PMID40911258
PMCPMC12647406

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.